United States Patent 7,989,589: Scope, Claim Structure, and Complement-Activation Peptide Landscape
US Patent 7,989,589 is directed to peptide compounds that inhibit complement activation, defined by a fixed structural motif (including two cysteines forming a disulfide bond) and a variable “Xaa” substitution framework that constrains allowed amino-acid identities and terminal modifications. The patent’s claim set is built to capture both specific exemplified sequences and narrow structural variants by controlling (i) positions that can vary, (ii) the acceptable chemical class for each variable, and (iii) whether aromatic indole/naphthyl analogs are used at the Trp position.
What follows is a claim-by-claim scope map, an interpretation of how the limitation language narrows coverage, and the resulting patent landscape risks and opportunities for designing around.
What does claim 1 cover in plain scope terms?
Core invention definition
Claim 1 is the broad independent claim and covers:
- A compound that inhibits complement activation
- Comprising a peptide with sequence:
Xaa1-Cys-Val-Xaa2-Gln-Asp-Trp-Gly-Xaa3-His-Arg-Cys-Xaa4
- Two Cys residues are joined by a disulfide bond
- Xaa positions are constrained to enumerated chemical identities/classes
- Xaa4 terminal carboxyl group may be replaced by NH2 (for permitted L/D-thr/ile/val/gly/asn cases)
Position-by-position substitution constraints
| Position |
Allowed content (as claimed) |
Scope implication |
| Xaa1 |
Ile, Val, Leu, Ac-Ile, Ac-Val, Ac-Leu, or a dipeptide comprising Gly-Ile |
Includes N-terminal capping (Ac-*) and one extended option (Gly-Ile). |
| Cys |
fixed |
Structural disulfide requirement anchors conformation. |
| Val |
fixed |
“Val” is not variable in claim 1. |
| Xaa2 |
Trp or an analog of Trp (peptidic or non-peptidic) |
This is the principal aromatic substitution lever. |
| Gln |
fixed |
No substitution allowed in claim 1. |
| Asp |
fixed |
No substitution allowed in claim 1. |
| Trp |
fixed |
This claim contains an additional “Trp” besides Xaa2; Xaa2 can also be aromatic-analog-like. |
| Gly |
fixed |
No substitution allowed. |
| Xaa3 |
His, Ala, Phe, or Trp |
Moderate latitude but limited to specific residues. |
| His |
fixed |
No substitution allowed. |
| Arg |
fixed |
No substitution allowed. |
| Cys |
fixed |
Disulfide partner. |
| Xaa4 |
L-Thr, D-Thr, Ile, Val, Gly, or a tripeptide comprising Thr-Ala-Asn; and the terminal carboxyl (where applicable) can be replaced by NH2 |
Controls C-terminus identity and allows carboxyamide in a limited set. |
Disulfide bond requirement
Claim 1 requires that the two cysteines are joined by a disulfide bond. That is a key enforceability and design constraint: many peptide variants can match sequence identity but fail to form the exact disulfide linkage state.
How do dependent claims narrow or expand coverage?
Claim 2
“Xaa1 is Ac-Ile.”
- Locks Xaa1 to a specific N-acetylated residue.
- This is not a restriction on disulfide, aromatic, or tail chemistry.
Claim 3
“Xaa3 is Ala.”
- Limits Xaa3 from the broader set (His/Ala/Phe/Trp) to Ala.
Claim 4
“Xaa2 is an analog of Trp comprising a substituted or unsubstituted bicyclic aromatic ring component or two or more substituted or unsubstituted monocyclic aromatic ring components.”
- Defines an explicit aromatic architecture requirement.
- This is broader than enumerating single analog molecules, but it is still restrictive: it requires bicyclic or multi-monocyclic components.
Claim 5
“Xaa2 is selected from … 2-naphthylalanine, 1-naphthylalanine, 2-indanylglycine carboxylic acid, dihydrotryptophan and benzoylphenylalanine.”
- Enumerates specific Trp-analog candidates.
- This dependent claim provides a clear infringement checkpoint because it ties aromatic substitution to a finite list.
Claim 6
“Xaa1 is Ac-Ile, Xaa2 is Trp or an analog of Trp … with substituted or unsubstituted indole, naphthyl or dibenzoyl component, Xaa3 is Ala and Xaa4 is L-Thr or D-Thr … with carboxy terminal —OH optionally replaced by —NH2.”
- This is a compound-definition tightening clause:
- Xaa1 fixed to Ac-Ile
- Xaa3 fixed to Ala
- Xaa4 restricted to L-Thr or D-Thr (with optional carboxyamide)
- Xaa2 allowed to be Trp or a narrower analog class, framed by indole/naphthyl/dibenzoyl components.
- Compared to claim 1, it removes multiple degrees of freedom (notably Xaa4).
Claim 7
“The compound of claim 6” having sequence selected from:
-
SEQ ID NO:4, 5, 6, 7, 8, 9, 10, 11, 12, 13
-
Claim 7 is the “named examples” lane, tethered to claim 6’s structural constraints.
-
It is the most direct route for asserting infringement: if an accused product matches one of the SEQ ID NO sequences exactly (including the disulfide state and terminal group), it falls squarely within claim 7.
Claim 8
“Xaa1 is a dipeptide Gly-Ile, and Xaa4 is a tripeptide Thr-Ala-Asn.”
- This defines a specific N-terminal extension (Gly-Ile) and a specific C-terminal tail (Thr-Ala-Asn).
- This dependent claim is structurally distinct from claim 6’s L/D-thr tail.
Claim 9
“The compound of claim 8, comprising a peptide having SEQ ID NO:14.”
- Claim 9 ties claim 8 to a specific exemplified sequence.
What is the effective claim “core” that drives infringement analysis?
Across claims, the most enforceable “core” elements are:
- Fixed peptide backbone positions: Cys-Val-Gln-Asp-Trp-Gly-His-Arg-Cys
- Disulfide bond between the two cysteines
- Controlled variability via Xaa1, Xaa2, Xaa3, Xaa4 enumerations and class definitions
- C-terminal limitation:
- Claim 1 allows several Xaa4 residues or Thr-Ala-Asn tripeptide
- Claim 6 restricts Xaa4 to L/D-Thr (with possible conversion of terminal OH to NH2)
Put differently: the patent does not claim “any complement-inhibiting peptide.” It claims peptides that meet a very specific topology and sequence architecture, with variable points limited to enumerated residues or aromatic substituent classes.
Where is the patent likely strongest for enforcement?
Best targets for infringement mapping
- Exact sequence matches to SEQ ID NO:4 through SEQ ID NO:13 (claim 7) and SEQ ID NO:14 (claim 9), since these are directly anchored to the narrowed claim 6 / claim 8 constraint sets.
- Products that keep the fixed backbone and disulfide while only varying within allowed Xaa1/Xaa2/Xaa3/Xaa4 enumerations.
Disulfide linkage state matters
If an accused product uses reduced cysteines, mismatched cystine connectivity, or different cyclization chemistry, it can fail the “two Cys … joined by a disulfide bond” limitation even if the linear peptide sequence matches.
Where is the claim likely easiest to design around?
The claim structure implies design-around options that fall outside its constrained variability:
- Change any fixed residue that is not listed as variable in claim 1
- Examples: changing Val, Gln, Asp, Trp (the backbone Trp), Gly, His, Arg from their fixed identities.
- Remove or alter the disulfide requirement
- e.g., engineering a non-disulfide stabilization or cysteine-to-something substitutions that prevent the Cys-Cys disulfide bond.
- Use Xaa2 aromatic substitution types not covered by claim 4/5 definitions
- Claim 4 is class-based (bicyclic or multi-monocyclic aromatic components), and claim 5 is enumerated to specific analogs.
- If an analog fails to meet those aromatic-architecture requirements, it can avoid claim coverage.
- Use Xaa4 identities outside the listed set
- Claim 1 restricts Xaa4 to L/D-Thr, Ile, Val, Gly, or Thr-Ala-Asn.
- Claim 6 narrows Xaa4 further to L/D-Thr (with optional conversion to NH2).
Claim coverage matrix: independent claim 1 vs dependent claim lanes
| Lane |
What is fixed |
What varies |
What this means for IP risk |
| Claim 1 (base) |
Backbone positions and disulfide |
Xaa1 (limited), Xaa2 (Trp/analog), Xaa3 (limited), Xaa4 (limited with terminal NH2 option) |
Broadest scope, but still tightly structured. |
| Claim 2/3 |
Narrows Xaa1 to Ac-Ile and/or Xaa3 to Ala |
Less freedom, more specificity |
These are narrower; they are helpful for enforcement but less for broad coverage. |
| Claim 4/5 |
Xaa2 must fit aromatic architecture list |
Xaa2 aromatic type |
Defines infringement boundaries for aromatic analog designers. |
| Claim 6/7 |
Strongly specified: Ac-Ile tail L/D-Thr (or amide) and Xaa3 Ala |
Xaa2 only under Trp/indole/naphthyl/dibenzoyl framing |
High confidence coverage for products matching exemplified sequences. |
| Claim 8/9 |
Gly-Ile at N-terminus and Thr-Ala-Asn at C-terminus |
Xaa2 limited by claim 8’s incorporation of claim 1 |
Separate “design family” at terminals. |
Patent landscape implications (scope-to-landscape mapping)
This patent is best understood as owning a specific chemical “family” rather than a whole complement-inhibition modality.
What the claims suggest about competitive space
- Complement activation inhibitors in peptides often exist as subclasses, but this patent’s language ties coverage to:
- a disulfide-stabilized peptide
- a fixed internal motif containing Gln-Asp-Trp-Gly-His-Arg
- a constrained set of aromatic analog rules for a Trp position
- defined N- and C-terminal residue choices, including a distinctive Thr-Ala-Asn tail in one lane
Where other patents are likely to overlap
In practice, overlap risk arises when competitors:
- Keep the internal motif and disulfide topology and only modify terminals or aromatic analog identities within the allowed sets.
- Use exactly the enumerated Trp analogs (claim 5) or sequences captured by SEQ ID NOs (claims 7 and 9).
Where other peptides can avoid overlap
Competitors can reduce risk by:
- Using a different complement target mechanism (if it yields different structure) and/or
- Using peptide architectures without the disulfide motif or without the fixed internal amino-acid pattern, and/or
- Selecting aromatic analog chemotypes not captured by the claim 4/5 definitions.
Key Takeaways
- US 7,989,589 claims disulfide-linked peptides that inhibit complement activation with a fixed backbone pattern:
Xaa1-Cys-Val-Xaa2-Gln-Asp-Trp-Gly-Xaa3-His-Arg-Cys-Xaa4
- Coverage hinges on four constrained variable positions (Xaa1, Xaa2, Xaa3, Xaa4) and a mandatory Cys-Cys disulfide bond.
- Claim 7 and Claim 9 provide the most enforcement-ready scope via SEQ ID NO:4-13 and SEQ ID NO:14, each tethered to narrower structural constraints.
- The patent is design-anchor heavy: altering fixed residues, disulfide connectivity, aromatic analog architecture, or allowed terminal residues is the most direct route to avoid capture under the claim language.
FAQs
1) Is claim 1 broad enough to cover any complement inhibitor peptide?
No. It covers only peptides that fit the specific sequence architecture and require a disulfide bond between the two cysteines, with enumerated/class-limited variability at Xaa1, Xaa2, Xaa3, and Xaa4.
2) What is the main freedom point for chemical variation?
Xaa2, because it can be Trp or constrained Trp analogs under claim 4 (bicyclic or multi-monocyclic aromatic architectures) and claim 5 (enumerated analog list).
3) Does the patent allow carboxamide formation at the peptide terminus?
Yes, but only where the claim permits Xaa4 to be L/D-Thr, Ile, Val, Gly, or Asn-containing tripeptide; it states the terminal —OH may be replaced by —NH2.
4) Which dependent claims most directly map to specific commercial products?
Claims 7 and 9 because they select compounds by SEQ ID NO ranges: SEQ ID NO:4-13 and SEQ ID NO:14.
5) What is the highest-risk design area for competitors?
Designing peptides that preserve the fixed motif and disulfide linkage, while changing only terminals or using Trp analogs from the claimed classes/enumerated list.
References
[1] US Patent 7,989,589 (claims as provided by user).
